Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in South Dakota?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A South Dakota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a South Dakota-licensed prescriber, including through telehealth under SDCL chapter 34-52, and can obtain a compounded peptide when it is eligible under federal 503A rules and dispensed by a pharmacy licensed by the South Dakota Board of Pharmacy, including a licensed nonresident pharmacy. SDCL 34-52-3 requires a proper provider-patient relationship with a diagnosis reached through acceptable medical practices, SDCL 34-52-5 requires a real-time audio and video exam whenever in-person care would call for a face-to-face visit, and South Dakota has no state bulks list, so peptide compounding eligibility follows the FDA framework.

Regulatory: Telehealth allowedRegulatory: Async unclearRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 4, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous unclear
Compounded GLP-1
Limited

Can a South Dakota resident get peptides by telehealth?

SDCL chapter 34-52 (Telehealth Utilization by Health Care Professionals, enacted in 2019 and amended in 2020 and 2021) defines telehealth to include interactive audio-video, interactive audio with store and forward, store-and-forward technology, and remote patient monitoring, and it defines store-and-forward technology as information stored for asynchronous delivery of care. The professional must be licensed in South Dakota (or be employed by a qualifying facility). SDCL 34-52-3 requires a proper provider-patient relationship, which includes verifying the patient's identity and location, disclosing the provider's credentials, obtaining consent, establishing a diagnosis through acceptable medical practices (history, examination, and any needed testing), discussing treatment options, arranging follow-up, and using technology sufficient to evaluate the condition. SDCL 34-52-5 requires a face-to-face examination by real-time audio and video before diagnosis and treatment whenever a face-to-face encounter would be required for the same service in person. SDCL 34-52-6 bars prescribing a controlled substance solely in response to an internet questionnaire or consult, including by telephone, without a proper relationship; GLP-1 medicines and the peptides in this database are not controlled, so that express bar does not reach them, but 34-52-3 and 34-52-5 still apply. This record classifies asynchronous prescribing as unresolved because the law is ambiguous: store-and-forward is inside the telehealth definition, but no provision says the relationship can be formed that way, and the real-time examination rule in 34-52-5 applies whenever in-person care would call for a face-to-face visit. The law also does not say whether a questionnaire alone can support a prescription for a drug that is not a controlled substance. [2]

How does the South Dakota pharmacy board treat compounding?

Compounding regulator for South Dakota
BoardSouth Dakota Board of Pharmacy (South Dakota Department of Health)
Eligible substancesFollows the federal 503A framework

The South Dakota Board of Pharmacy licenses pharmacies and pharmacists under SDCL chapter 36-11 and regulates practice through Administrative Rules of South Dakota article 20:51, with compounding practices in chapter 20:51:31. SDCL 36-11-19.3 requires any nonresident pharmacy to be licensed before doing business in South Dakota, to be licensed and in good standing in its home state, and to submit its most recent home-state inspection report, so an out-of-state pharmacy shipping to South Dakota patients needs a South Dakota nonresident license. The compounding chapter was rewritten effective June 2, 2024, when the older sterile compounding rules (20:51:31:02 to 20:51:31:31) were repealed, and amended again effective September 15, 2025 (52 SDR 27): rule 20:51:31:32 now requires all sterile and nonsterile compounding to follow federal law and the February 1, 2024 USP chapters 797, 795, 800, and 825, and rules 20:51:31:33 and 20:51:31:34 require a compounding policy and procedure manual with a quality assurance program and USP physical, equipment, and environmental standards. South Dakota has not adopted its own list of compoundable bulk substances; the federal 503A test applies (approved drug component, USP or NF monograph, or FDA 503A bulks list). [1] [3] [4] [5] [6]

Can you get compounded GLP-1s in South Dakota?

Regulatory: Compounded GLP-1 limited

South Dakota has not published a state rule that is looser than FDA policy. Because many South Dakota patients use mail order, confirming that the dispensing pharmacy holds a South Dakota nonresident license is the main practical check. [1] [3] [9]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in South Dakota?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in South Dakota

What you'll actually find in South Dakota, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [11] [12] [13]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]

What South Dakota has done

PeptideAgent has not found a board or legislative action on peptides in South Dakota.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [16] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [17] [18] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in South Dakota. The state law we checked does not settle whether a prescription can be issued without a live visit, so expect one. [2] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the South Dakota Board of Pharmacy (South Dakota Department of Health); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [15]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [14]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [7] [19] [20]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [15] [21] [22]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [13] [22] [23]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [14] [24] [25] [26] [27] [28]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [14]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [15]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [13]
  • Pharmacy: Is this made for me on a prescription written in my name? [23]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [13] [22]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [13]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in South Dakota?

SDCL chapter 36-11 reserves dispensing of prescription drugs to licensed pharmacies and pharmacists, so shipping "research use only" injectable peptides to South Dakota consumers is not a licensed pharmacy activity. [3] [10]

Peptide-specific notes for South Dakota

No peptide-specific rule identified for this jurisdiction. The general compounding and telehealth rules above apply, and the federal record covers semaglutide, tirzepatide, and BPC-157.

Frequently asked questions

Can I get a GLP-1 prescription in South Dakota through telehealth?

Yes, from a provider licensed in South Dakota (or employed by a facility listed in SDCL 34-52-2) who first establishes a proper provider-patient relationship under SDCL 34-52-3. That relationship requires identity verification, consent, a diagnosis based on examination and any needed tests, a discussion of options, and follow-up care. SDCL 34-52-5 also requires a real-time audio and video examination whenever the same care in person would call for a face-to-face visit. [2]

Does South Dakota allow prescribing from an online questionnaire?

South Dakota law does not settle this for drugs that are not controlled substances. SDCL 34-52-6 bars prescribing a controlled substance solely in response to an internet questionnaire or consult, including by telephone, without a proper provider-patient relationship. GLP-1 drugs are not controlled, so that bar does not reach them. SDCL 34-52-3 still requires a proper relationship with a diagnosis reached through acceptable medical practices, and SDCL 34-52-5 requires a real-time audio and video examination whenever the same care in person would call for a face-to-face visit. [2]

Does an out-of-state pharmacy need a South Dakota license to ship me compounded peptides?

Yes. SDCL 36-11-19.2 and 36-11-19.3 define nonresident pharmacies and require them to be licensed by the South Dakota Board of Pharmacy, with proof of good standing in their home state. Check the Board's license lookup before ordering. [1] [3] [4]

Which rules govern compounding in South Dakota?

Compounding is governed by SDCL chapter 36-11 and Administrative Rules of South Dakota chapter 20:51:31, which since September 15, 2025 requires compounding to follow federal law and the February 1, 2024 USP compounding chapters. South Dakota has no state bulks list, so a peptide must be an approved drug component, have a USP or NF monograph, or be on the FDA 503A bulks list. [3] [5] [6]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]South Dakota Board of Pharmacy (South Dakota Department of Health)
  2. [2]South Dakota Codified Laws chapter 34-52, Telehealth utilization by health care professionals
  3. [3]South Dakota Codified Laws chapter 36-11, Pharmacists and pharmacies (including nonresident pharmacy licensure, 36-11-19.2 and 36-11-19.3)
  4. [4]South Dakota Codified Laws 36-11-19.3, Nonresident pharmacy licensure
  5. [5]Administrative Rules of South Dakota chapter 20:51:31, Compounding practices (amended effective September 15, 2025)
  6. [6]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  7. [7]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  8. [8]FDA: Pharmacy Compounding Advisory CommitteeFDA
  9. [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  10. [10]21 U.S.C. 331, Prohibited acts

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 4). Are peptides legal in South Dakota?. https://peptideagent.ai/legal/south-dakota
HTML link
<a href="https://peptideagent.ai/legal/south-dakota">Are peptides legal in South Dakota?</a>, PeptideAgent, updated October 4, 2026.